This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Check our privacy policy here
Our Blog
SunRock Biopharma and Escugen Forge Alliance to Develop First-in-Class CCR9-Targeted ADC
17/06/2025SunRock Biopharma and Escugen Forge Alliance to Develop First-in-Class CCR9-Targeted ADC Santiago de Compostela, Spain, and Shanghai, China . June 16,…
Read More
SunRock is pleased to share a new publication in Molecular Oncology highlighting the potential of SRB2 in pancreatic ductal adenocarcinoma
03/06/2025SRB2 is a humanized monoclonal #antibody developed by SunRock Biopharma, S.L targeting #CCR9. 🎯 This study demonstrates the efficacy of SRB2…
Read More
SunRock Biopharma, S.L will be attending the BIOInternational 2025 in Boston from 16-19 June
28/05/2025We are a biotech company with a pipeline of therapeutic antibodies for the treatment of cancer and immune-mediated inflammatory diseases, including…
Read More
SunRock Biopharma, S.L will be attending the BIOEquity 2025 in Bruges from 12-14 May
05/05/2025We are a biotech company with a pipeline of therapeutic antibodies for the treatment of cancer and immune-mediated inflammatory diseases, including…
Read More
SunRock Biopharma, S.L will be attending the BIOEurope Spring 2025 in Milan from 17-19 March
04/03/2025We are a biotech company with a pipeline of therapeutic antibodies for the treatment of cancer and immune-mediated inflammatory diseases, including…
Read More
SunRock Biopharma will be attending the 20th Congress of ECCO European Crohn’ and Colitis Organisation in Berlin from 19-22 February
12/02/2025We are a hashtag#biotech company with a pipeline of therapeutic hashtag#antibodies for the treatment of hashtag#inflammatory hashtag#bowel hashtag#disease. Are you attending…
Read More
La compostelana SunRock y el Instituto de OncologĂa del Vall d’Hebron reciben 1,8 millones de euros de la Agencia Estatal de InvestigaciĂłn para el desarrollo de nuevos anticuerpos en el tratamiento del cáncer de ovario
07/02/2025El consorcio integrado por SunRock Biopharma, con sede en el Biopolo Sionlla, y por VHIO lidera el proyecto OVERCAD,…
Read More
SunRock Biopharma will be giving an oral presentation on its anti-CCR9 antibody for IBD in ECCO25, Berlin.
31/01/2025SunRock’s communication has been selected for oral presentation at the 20th Congress of ECCO, February 19-22, 2025, Berlin, Germany. DOP065 SRB1:…
Read More
Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers
08/01/2024Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today secured an…
Read More
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-Treat Cancers
21/09/2023September 21, 2023 Debiopharm to boost its ADC oncology pipeline through multi-asset partnership with SunRock’s antibody portfolio integrating Multilink™ & AbYlink™…
Read More
